Clinical Trials

2 studies in Symptom Management

1. Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy Scottsdale and Phoenix, AZ View Summary
   Close

   Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

   Location:

   Scottsdale and Phoenix, AZ

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Severe nausea and/or vomiting in patients receiving radiotherapy to the upper abdomen is common despite having received pre-medication with ondansetron, a standard preventive treatment. This study aims to reduce the incidence of significant nausea and/or vomiting with the addition of the NK1-antagonist aprepitant to standard ondansetron treatment. This study will also assess the safety and tolerability of prolonged administration of aprepitant over the 4 to 6 week period of radiation treatment.

   NCT ID:

   NCT00970905

   IRB Number:

   10-002651

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   
   Scottsdale: Clinical Trials Referral Office 507-538-7623
                       
   
   

   Request Information Online
2. EUS Guided Celiac Neurolysis Rochester, MN View Summary
   Close

   EUS Guided Celiac Neurolysis

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   - Hypothesis: - Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. - Rationale: - Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.

   NCT ID:

   NCT01615653

   IRB Number:

   09-005037

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Michael J Levy, MD 507-266-6931
                       
   
   
   

   Request Information Online